先進治療薬の世界市場

先進治療薬の世界市場は2030年までに254億米ドルに達する見込み

2024年に130億米ドルと推定される先進治療薬の世界市場は、2024年から2030年にかけてCAGR 11.8%で成長し、2030年には254億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである組織工学製品は、CAGR 12.5%を記録し、分析期間終了時には105億米ドルに達すると予測されます。細胞治療分野の成長率は、分析期間のCAGRで11.1％と推定されます。

米国市場は56億米ドルと推定、中国はCAGR10.2％で成長予測

米国の先進治療薬市場は、2024年には56億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.2％となります。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.9%と8.8%と予測されています。欧州では、ドイツがCAGR約12.9%で成長すると予測されています。

世界の先進治療薬市場- 主要動向と促進要因まとめ

先進治療薬（ATMPs）は、先進的な生物学的手法によって疾患の治療、診断、予防を行うように設計された遺伝子治療、細胞治療、組織工学製品を包含し、医療イノベーションのフロンティアを代表するものです。ATMPは、様々ながん、遺伝性疾患、変性疾患など、現在従来の医薬品では治療が困難あるいは不可能な疾患に対する画期的な治療法を提供します。これらの治療は、細胞の遺伝子を改変したり、身体自身の修復機構を利用したり、損傷した組織を置き換えたりすることで機能し、高度に個別化された、治癒の可能性のある治療を提供します。ATMPの開発と承認は、その安全性、有効性、品質を保証する厳しい規制プロセスの対象となります。

ATMPsの分野は、バイオテクノロジーの著しい進歩と遺伝子および細胞メカニズムのより深い理解により、急速な進歩を遂げています。CRISPR-Cas9遺伝子編集、人工多能性幹細胞（iPSC）、高度な組織足場技術などの開発により、効果的で的を絞った治療法開発の可能性が広がっています。FDAやEMAなどの規制機関によるATMPの臨床試験の増加や承認の成功は、その治療的可能性と市場性を浮き彫りにしています。学術機関、バイオテクノロジー企業、製薬大手間の共同研究は、開発パイプラインを加速し、より多くのATMPを商業化に近づけています。さらに、製造技術やスケーラブルな生産プロセスの進歩により、これらの治療薬がより利用しやすく、費用対効果も高くなっています。

ATMP市場の成長は、いくつかの要因によってもたらされます。第一に、従来の治療では十分に対処できないことが多い慢性疾患や遺伝性疾患の有病率の増加が、ATMPのような革新的な治療薬への需要を促進しています。第二に、バイオテクノロジーと遺伝子工学の著しい進歩が、より効果的で個別化されたATMPの開発を可能にしています。第三に、バイオテクノロジー企業や製薬会社による研究開発への多額の投資が、新たなATMPの発見と商業化を加速させています。さらに、画期的治療薬に対する良好な規制環境と迅速な承認経路が、ATMPの迅速な市場参入を促進しています。最後に、ATMPの製造・流通インフラの拡大と相まって、先端療法の利点に対する患者や医師の意識の高まりが、市場の成長をさらに後押ししています。

セグメント

製品タイプ（組織工学製品、細胞療法、遺伝子療法、CAR-T療法）

調査対象企業の例

• Bluebird Bio Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene, Inc.
• MEDIPOST Co., Ltd.
• Novartis AG
• Organogenesis Inc.
• Spark Therapeutics, Inc.
• UniQure N.V.
• Vericel Corporation

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Advanced Therapy Medicinal Products Market to Reach US$25.4 Billion by 2030

The global market for Advanced Therapy Medicinal Products estimated at US$13.0 Billion in the year 2024, is expected to reach US$25.4 Billion by 2030, growing at a CAGR of 11.8% over the analysis period 2024-2030. Tissue Engineered Products, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$10.5 Billion by the end of the analysis period. Growth in the Cell Therapy segment is estimated at 11.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 10.2% CAGR

The Advanced Therapy Medicinal Products market in the U.S. is estimated at US$5.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

Global Advanced Therapy Medicinal Products Market - Key Trends & Drivers Summarized

Advanced Therapy Medicinal Products (ATMPs) represent a frontier in medical innovation, encompassing gene therapies, cell therapies, and tissue-engineered products designed to treat, diagnose, or prevent diseases through advanced biological methods. ATMPs offer groundbreaking treatments for conditions that are currently difficult or impossible to treat with conventional medicines, including various cancers, genetic disorders, and degenerative diseases. These therapies work by modifying the genetic makeup of cells, harnessing the body's own repair mechanisms, or replacing damaged tissues, thus providing highly personalized and potentially curative treatments. The development and approval of ATMPs are subject to stringent regulatory processes, ensuring their safety, efficacy, and quality.

The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.

The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs. Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.

SCOPE OF STUDY:

The report analyzes the Advanced Therapy Medicinal Products market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Tissue Engineered Products, Cell Therapy, Gene Therapy, CAR-T Therapy)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 190 Featured) -

• Bluebird Bio Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene, Inc.
• MEDIPOST Co., Ltd.
• Novartis AG
• Organogenesis Inc.
• Spark Therapeutics, Inc.
• UniQure N.V.
• Vericel Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • A Prelude to Advanced Therapy Medicinal Products (ATMP)
  • ATMPs' Costs and Availability
  • Global Economic Outlook
  • Tariff Impact on Global Supply Chain Patterns
  • Global Market Prospects and Outlook
  • Advanced Therapy Medicinal Products Market Poised to Witness Rapid Growth
  • Growth Drivers and Challenges
  • ATMP Marketing Authorisations: An Insight
  • North America and Europe Dominate, Asia-Pacific to Exhibit Fastest Growth
  • Competition
  • Recent Market Activity
  • Advanced Therapy Medicinal Products - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders Drive Market Demand
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Regenerative Medicine: A Promising Area for Advanced Therapy Medicinal Products
  • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration
  • Rising Demand for Gene Therapy Spurs Market Expansion
  • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
  • Top Ten Genetic Diseases Worldwide
  • Oncology Represents the Largest Indication for Gene Therapy
  • Uptrend in Healthcare Spending Creates Fertile Environment
  • Expanding Role of Advanced Therapy Medicinal Products Market in Personalized Medicine
  • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
  • Biotech Research Spending Patterns Steer Momentum
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Advanced Therapy Medicinal Products Market Analysis of Annual Sales in US$ Million for Years 2022 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Tissue Engineered Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Tissue Engineered Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for CAR-T Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for CAR-T Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 12: USA Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 13: USA 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 15: Canada 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• JAPAN
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 16: Japan Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 17: Japan 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• CHINA
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 18: China Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 19: China 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• EUROPE
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 20: Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 22: Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• FRANCE
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 24: France Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: France 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• GERMANY
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 26: Germany Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Germany 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• ITALY
  • TABLE 28: Italy Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Italy 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• UNITED KINGDOM
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 30: UK Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: UK 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 32: Rest of Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Rest of Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• ASIA-PACIFIC
  • Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 34: Asia-Pacific Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Asia-Pacific 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 36: Rest of World Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Rest of World 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030

IV. COMPETITION